Breast Cancer Clinical Trial

Expanded Access Protocol for Subjects Previously Treated With Gedatolisib in B2151009

Summary

Continued access to treatment for subjects who continue benefit from therapy with gedatolisib in combination with palbociclib, and fulvestrant or letrozole.

View Full Description

Full Description

The primary purpose of this study is to provide continuing access to treatment for subjects who continue benefit from therapy with gedatolisib in combination with palbociclib, and fulvestrant or letrozole.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Currently enrolled in the B2151009 clinical study and benefiting from treatment with gedatolisib in combination with other therapies as determined by the Investigator
Previously demonstrated compliance and are willing and able to comply with scheduled visits, treatment plans, and other study procedures
No evidence of progressive disease, as determined by the Investigator
Provide written informed consent prior to enrolling and receiving treatment

Exclusion Criteria:

Permanently discontinued from treatment in Study B2151009, or discontinued from Study B2151009 for any reason
Women who are pregnant, intend to become pregnant, or nursing

Study is for people with:

Breast Cancer

Study ID:

NCT05134922

Recruitment Status:

Available

Sponsor:

Celcuity, Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 5 Locations for this study

See Locations Near You

University of Alabama at Birmingham
Birmingham Alabama, 35233, United States More Info
Erica Stringer-Reasor, MD
Contact
[email protected]
University of Michigan
Ann Arbor Michigan, 48109, United States More Info
Anne F Schott, MD
Contact
734-936-6266
[email protected]
Ohio State University Comprehensive Cancer Center
Columbus Ohio, 43210, United States More Info
Robert Weslowski, MD
Contact
[email protected]
The University of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States More Info
Rachel Layman, MD
Contact
[email protected]
Seattle Cancer Care Alliance
Seattle Washington, 98109, United States More Info
Jennifer Specht, MD
Contact
206-606-6768
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Study ID:

NCT05134922

Recruitment Status:

Available

Sponsor:


Celcuity, Inc.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider